Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Still a Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $44.53 and last traded at $44.19, with a volume of 61355 shares. The stock had previously closed at $43.20.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Finally, Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus target price of $52.33.

Kiniksa Pharmaceuticals International Stock Performance

The company has a market cap of $3.33 billion, a P/E ratio of 97.69 and a beta of 0.04. The business’s 50-day moving average price is $41.63 and its 200 day moving average price is $37.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.18) earnings per share. Equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the completion of the transaction, the chief financial officer directly owned 31,086 shares of the company’s stock, valued at $1,289,758.14. The trade was a 57.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Eben Tessari sold 12,470 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.24, for a total transaction of $514,262.80. Following the completion of the transaction, the chief operating officer owned 22,714 shares in the company, valued at approximately $936,725.36. This represents a 35.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 202,130 shares of company stock valued at $8,019,579 over the last 90 days. 53.48% of the stock is owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Amundi acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after buying an additional 1,002 shares during the period. Millennium Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Kiniksa Pharmaceuticals International by 13.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 15,410 shares of the company’s stock worth $430,000 after buying an additional 1,846 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth $233,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.